Physician profile
Lauren E Moore
NPI 1487286027
$4,864.67
in general payments reported to CMS, 2019-2025
23 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $354 · 2023: $1,478 · 2024: $1,482 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,258 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,258.16 |
| Education | $252.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,015.34 | 2022-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $702.46 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $516.47 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $473.27 | 2022-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $441.23 | 2023-2025 | |
| Lilly USA, LLC | $363.40 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $236.17 | 2023-2025 | |
| Dermavant Sciences, INC. | $226.20 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $163.41 | 2023-2025 | Ilumya, Odomzo |
| Janssen Scientific Affairs, LLC | $150.00 | 2022 | |
| Organon LLC | $76.35 | 2025 | Vtama |
| Pfizer INC. | $70.27 | 2024-2025 | |
| Ucb, INC. | $68.24 | 2025 | Bimzelx |
| Biofrontera INC. | $67.19 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $63.57 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.41 | 2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $44.94 | 2023-2025 | Libtayo |
| Novo Nordisk INC | $25.42 | 2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $24.93 | 2023 | Sotyktu |
| Neuronetics, INC. | $24.66 | 2025 | Neurostar Tms Therapy System |
| Verrica Pharmaceuticals INC. | $23.03 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.49 | 2022 | |
| Incyte Corporation | $19.22 | 2024 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.